Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator initiated, prospective, randomized, controlled study in order to evaluate the effect of anti-thymocyte globulin (Fresenius ATG) on engraftment, graft versus host disease (GVHD) and graft versus leukemia (GVL) effect in haplo-identical allogeneic haematopoietic stem-cell transplantation.

Next Previous
Search
Trial Profile

An investigator initiated, prospective, randomized, controlled study in order to evaluate the effect of anti-thymocyte globulin (Fresenius ATG) on engraftment, graft versus host disease (GVHD) and graft versus leukemia (GVL) effect in haplo-identical allogeneic haematopoietic stem-cell transplantation.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Graft-versus-host disease; Leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Mar 2011 Actual end date (1 Sep 2010) added as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Planned end date changed from 1 Jan 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top